US Senate asks Novartis to shed light on data manipulation allegations
The one-time treatment for spinal muscular atrophy costs $2.1 million (CHF2.1 million).
Keystone / Yannick Bailly
The Swiss pharmaceutical firm Novartis has been asked to provide details regarding possible data inaccuracies for its human gene therapy Zolgensma – the world’s most expensive treatment.
Novartis has been accused of withholding information about manipulated data during early testing of Zolgensma, a one-time $2.1 million (CHF2.1 million) treatment for spinal muscular atrophy (SMA), the leading genetic cause of death in infants. The treatment was approved by the US Food and Drug Administration (FDA) in May.
Novartis said its subsidiary in California began investigating the alleged data manipulation for Zolgensma as soon as it learned about it. The company claims that it shared the information with the FDA as soon as it had the interim conclusions.
The chairman of the US Senate Finance Committee, Chuck Grassley, wants to have access to internal reports and to know exactly when the group became aware of the data manipulation. The Basel-based pharmaceutical giant has until August 23 to shed light on the situation. Novartis has acknowledged receipt of this request.
Despite the allegations, the FDA reported last week that it retains full confidence in the new treatment. However, it plans to take the case to court, as the pharmaceutical group was aware of the problem before receiving the green light to market it at the end of May.
“The agency will use its full authorities to take action, if appropriate, which may include civil or criminal penalties,” said an FDA statement last weekExternal link.
Novartis has blamed several employees of its subsidiary Avexis, but according to several analysts this case could cost it dearly. Zolgensma has yet to receive the green light from authorities in the European Union and Japan.
More
More
Novartis rejects suspected data manipulation in US
This content was published on
Swiss pharma giant Novartis has dismissed criticism that it allegedly withheld information about animal testing data inaccuracies to US authorities.
Lucerne voters back fast-tracked wind energy expansion
This content was published on
The construction of large wind turbines in the canton of Lucerne should not be delayed by lengthy approval procedures. Voters have spoken out in favor of curtailing municipal autonomy and a cantonal planning approval procedure.
Valais voters reject plan to achieve carbon neutrality by 2040
This content was published on
Voters in canton Valais in southern Switzerland have turned down a proposal for the region to achieve carbon neutrality by 2040.
Swiss central banker wants to boost equity to head off risks
This content was published on
Equity levels at the Swiss National Bank (SNB) are much too low for the risks its large balance sheet poses, according to Martin Schlegel.
Beer sales in Switzerland watered down by bad weather
This content was published on
The past brewing year fell through in Switzerland, partly due to the bad weather. Beer sales shrank again. For the first time, per capita consumption fell below the 50 liter mark.
Compensation for Syrian after pregnant wife denied help on Swiss train
This content was published on
Switzerland’s Federal Court has partially upheld the appeal of a Syrian family being deported from Switzerland to Italy in 2014. The man now also receives compensation.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
High pharma margins squeeze health systems
This content was published on
Curing cancer for the masses could be challenging if healthcare systems are crippled by rapidly rising cancer drug prices.
The pharma holy grail: drugs for you, designed by you
This content was published on
In the age of sensors, wearables, and artificial intelligence (AI), almost everything can be customised for the individual.
Push for drug pricing transparency strikes a nerve with industry
This content was published on
The 72nd World Health Assembly opens on Monday, but a draft resolution to end secrecy around drug pricing has already struck a nerve.
Pharma company Sandoz named in US price-fixing lawsuit
This content was published on
The Germany-based subsidiary of Novartis is targeted in a 44-state class action suit for breaching rules on fair competition.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.